BTC Health Limited logo

BTC Health Limited (BTC)

Market Closed
CXA CXA
- Market Cap
- P/E Ratio
0% Div Yield
1,515 Volume
0 Eps
Want to track BTC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

BTC closed Wednesday higher, an increase of 11.86% from Tuesday's close, completing a monthly increase of 0%. Over the past 12 months, BTC stock gained 17.86%.
BTC is not paying dividends to its shareholders.
BTC Health Limited has completed 1 stock splits, with the recent split occurring on Nov 20, 2024.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on CXA (AUD).

BTC Health Limited Dividends

BTC is not paying dividends to its shareholders.

BTC Health Limited Earnings

BTC have yet to publish their earning reports.
BTC is not paying dividends to its shareholders.
BTC have yet to publish their earning reports.

BTC Health Limited (BTC) FAQ

On which exchange is it traded?

BTC Health Limited is listed on CXA.

What is its stock symbol?

The ticker symbol is BTC.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, no market cap data is available.

Has BTC Health Limited ever had a stock split?

BTC Health Limited had 1 splits and the recent split was on Nov 20, 2024.

BTC Health Limited Profile

Biotechnology Industry
Healthcare Sector
Mr. Joshua Kahanovitz CEO
CXA Exchange
- ISIN
Australia Country
- Employees
- Last Dividend
20 Nov 2024 Last Split
- IPO Date

Overview

BTC Health Limited is a notable Pooled Development Fund, meticulously managed by LHC Capital Partners Pty Ltd. The fund is especially focused on the investment within the healthcare and biotechnology sectors, operating across various stages including seed/startup, early venture, mid venture, late venture, emerging growth, and growth capital investments. BTC Health Limited showcases a strategic interest towards advancing technologies and innovations in post-genomics, stem cell biology, convergence, silicon biology, and nanomedicine. The investments are primarily directed towards companies based in Australia and New Zealand, encompassing both listed and unlisted entities. This strategic approach allows BTC Health Limited to contribute significantly to the advancement of healthcare and biotechnology, fostering groundbreaking discoveries and innovations.

Products and Services

List of investment focus areas within the healthcare and biotechnology sector:

  • Post-Genomics:

    Investment in functional genomics, transcriptomics, proteomics, structural genomics, glycomics, and pharmacogenomics. This area explores the complexity of genomics beyond the DNA sequence itself, fostering advancements in understanding how genes and their products interact within an organism.

  • Stem Cell Biology:

    Focuses on stem cell therapies, encompassing the development and utilization of stem cells to repair or replace damaged tissues and organs. This has the potential to revolutionize treatments for various diseases and injuries.

  • Convergent Technologies:

    Investments in biomaterials, bionics, biosensors, tissue engineering, microfluidics, and moletronics. These technologies represent the convergence of biological and engineering systems, which could lead to new innovations in medical devices, diagnostics, and tissue repair strategies.

  • Silicon Biology:

    Centers on structure-based drug design, virtual screening, computational library design, and in silico ADME/tox. Silicon biology involves the application of computational methodologies to biological problems, particularly drug discovery and development, offering faster and more efficient pathways to new medicines.

  • Nanomedicine:

    Although not explicitly detailed in the description, the inclusion of nanomedicine suggests investments in the medical application of nanotechnology. This field holds promise for revolutionary advancements in diagnostics, imaging, and targeted therapies, offering the potential for more personalized and precise medical treatments.

Contact Information

Address: Suite 201
Phone: 61 2 8031 7707